Who We Are

Rick Hiatt

Rick Hiatt, Enigma’s CEO and Board Chairman, has more than 30 years of experience in the radiopharmaceutical industry. Mr. Hiatt served as Vice President of Supplier Relations and Business Logistics at Syncor International (now Cardinal Health) and as Vice President of Global Business Development at CTI/Siemens Molecular Imaging. He then launched Cerveau Technologies, Inc. and Meilleur Technologies, Inc., and led them to their successful acquisition by Lantheus Medical Imaging. In addition to his responsibilities as a successful entrepreneur, Mr. Hiatt sits on the Board of the McGill Research Center of Studies in Aging.

Jack Coffey

• Previously Sr. VP of Quality & Regulatory for Cardinal Health Nuclear Pharmacy Services
• VP of Quality & Regulatory, Syncor International (now Cardinal Health)

Dr. Samantha Budd Haeberlein

Enigma’s Chief Medical Officer, has more than 20 years of experience in the pharmaceutical industry across discovery research, translational science, and clinical development. Prior to joining Enigma, Dr. Haeberlein served as Vice President at AstraZeneca and Senior Vice President at Biogen. She also sits on the Boards of ALZPath, Vigil Neuroscience, and The Boston Home.

As Chief Medical Officer, Dr. Haeberlein’s responsibilities include providing operational and strategic decision-making while overseeing all facets of clinical development, including clinical operations, medical monitoring, pharmacovigilance, and statics and data management, as well as supporting effective progress of the company’s product pipeline. Dr. Haeberlein collaborates with key internal partners, including the Chief Science Officer, and with external stakeholders, including contract research organizations, internal and external experts, and global health authorities.

Dr. Hartmuth Kolb

Hartmuth C. Kolb, Ph.D., is Chief Scientific Officer at Enigma Biomedical Group USA. He is internationally recognized as a co-founder of click chemistry, honored with the 2022 Nobel Prize in Chemistry (Sharpless, Meldal, Bertozzi). Dr. Kolb has more than 30 years of experience in academia and the biopharmaceutical industry, including senior leadership roles at Siemens, Johnson & Johnson/Janssen, and Avid Radiopharmaceuticals/Eli Lilly. He co-invented the first FDA-approved tau PET tracer, [18F]Flortaucipir (Tauvid), and developed the first blood test for Alzheimer’s disease pathology (plasma p217Tau). His research spans molecular imaging probes for cancer, cardiovascular, and neuroscience applications, many of which have advanced into human studies. Dr. Kolb has authored over 100 peer-reviewed publications, is co-inventor on more than 40 patents, and has been cited over 45,000 times (h-index 66). As Chief Scientific Officer, he oversees discovery, testing, licensing evaluations, and the translation of preclinical projects into human studies.

Serge Gauthier, M.D.

Dr. Gauthier is a preeminent researcher in the field of Alzheimer’s disease and an Emeritus Professor of Neurology and Psychiatry at McGill University. Dr. Gauthier also serves as Editor-in-Chief of the Journal of Prevention of Alzheimer’s disease.

Dr. Eric Reiman

Dr. Reiman is the CEO, Banner Alzheimer’s Institutes, (BAI), Executive Director, BAI-Phoenix, BAI-Tucson and Banner Sun Health Research Institute, Professor of Psychiatry at the University of Arizona, University Professor of Neuroscience at Arizona State University, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium, a leader of the Alzheimer’s Prevention Initiative (API), co-founder of ALZPath, and Chairman of the Flinn Foundation Board of Directors. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarker, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s and related diseases, the accelerated evaluation of Alzheimer’s prevention therapies, and new models of research collaboration and clinical care. He is an author of >700 publications, a principal investigator of several large NIH grants, other grants, and contracts, a former member of NIA Council, and a recipient of the Potamkin Prize.

Keith Johnson M.D., Ph.D.

Dr. Keith Johnson is a Professor of Radiology and Neurology at the Harvard Medical School. He is also an Associate Radiologist and the Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital (MGH). Dr. Johnson also serves as an associate physician and staff neurologist in the Memory Disorders Unit at the Brigham and Women’s Hospital as well as a Clinical Associate in Neurology at the MGH.

Dr. Johnson is co-director of the Neuroimaging Program of the Massachusetts Alzheimer’s disease Research Center and its Dominantly Inherited Alzheimer Network research initiatives. He oversees the Clinical Brain Positron Emission Tomography Service at the MGH and also practices as a neurologist that specializes in neurodegenerative disorders.

Dr. Sterling Johnson

Dr. Sterling Johnson is the Jean R. Finley Professor of Geriatrics and Dementia in the Department of Medicine, Division of Geriatrics and Gerontology, at the University of Wisconsin. A clinical neuropsychologist with research interests in early identification of Alzheimer’s disease and related disorders, Dr. Johnson leads the Wisconsin Registry for Alzheimer’s Prevention, a longitudinal cohort study of 1500+ people at varying levels of risk for sporadic Alzheimer’s disease. He is also the lead principal investigator for the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI). ADRC’s nationwide collaborat in CLARiTI for the purpose of elucidating the multiple intersecting etiologies that cause cognitive impairment and that may be present in any given patient. CLARiTI launched in 2023 and will establish standardized brain imaging and blood plasma test protocols to analyze levels and types of amyloid and tau, which are hallmark biomarkers of Alzheimer’s disease, together with assays of other proteinopathies.

Kenji Ishii, M.D.

Dr. Kenji Ishii is the Leader of Diagnostic Neuroimaging Research at Tokyo Metropolitan Institute of Gerontology. Dr. Ishii’s research interests are focused on the physiology of brain aging and pathophysiological mechanisms in aging brain disorders such as Alzheimer’s disease and Parkinson’s disease.

Prof. Christopher Rowe

Prof. Christopher Rowe, BMBS, FRACP, MD, FAANMS is a nuclear medicine physician and neurologist, with over 20 years of experience in dementia research and patient care. He is the Director of Molecular Imaging Research at Austin Health, Melbourne, Professorial Fellow University of Melbourne, a NHMRC Practitioner Fellow and is the inaugural Director of the Australian Dementia Network. His research focus is molecular imaging and blood diagnostics of neurodegenerative diseases, particularly Alzheimer’s disease, for better understanding, earlier more accurate detection, and to facilitate development of early therapeutic interventions. He has over 400 publications, is in the 2021 Highly Cited Researcher list of the top 1% world-wide for neuroscience with over 7,500 citations of his papers per year, and has received the 2011 US Society of Nuclear Medicine Kuhl-Lassen Award for Outstanding Contribution to Brain Imaging and the 2016 Christopher Clark Award for advancing human brain amyloid imaging.

Dr. Koen Van Laere

Prof. Dr. Koen Van Laere is the Chair of the Department of Imaging and Pathology at the KU Leuven University and the Head of the Division of Nuclear Medicine at the Leuven University Hospital.

Prof. Henrik Zetterberg

Prof. Henrik Zetterberg, whose background is in molecular biology and medicine, has spent the past 25 years focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders, and has become a world expert in this field. He has published more than 2,600 scientific articles and has received numerous awards.

Dr. Richard Hargreaves

Dr. Richard Hargreaves serves as Senior Vice President of Bristol Myers Squibb’s Neuroscience, Immunology, Integrative Sciences and Cardiovascular (NIIC) Research groups where he is working to build and expand the company’s drug discovery pipeline. By collaborating with specialty biotech and academic partners across the neuroscience field, as well as utilizing Bristol Myers Squibb’s expertise in proteomics, protein homeostasis, inflammation and immunology, Dr. Hargreaves and his team are working to discover and develop treatments for patients living with neurodegenerative diseases. In addition to biotech and academic research partners, Dr. Hargreaves is also committed to partnering with key advocacy organizations, to ensure that the patient voice and perspective are fully heard in industry research.